{
    "clinical_study": {
        "@rank": "87565", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if lobucavir is a safe and effective treatment for\n      cytomegalovirus in patients with AIDS."
        }, 
        "brief_title": "A Study of Lobucavir in Patients With AIDS", 
        "condition": [
            "Cytomegalovirus Infections", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cytomegalovirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly\n      clinic visits are required."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Aerosolized pentamidine.\n\n          -  TMP / SMX.\n\n          -  Isoniazid.\n\n          -  Dapsone.\n\n          -  Fluconazole.\n\n          -  Ketoconazole.\n\n          -  Rifabutin.\n\n          -  Fluoxetine HCl.\n\n          -  Acetaminophen.\n\n          -  Antacids.\n\n          -  Metamucil.\n\n          -  Multivitamins.\n\n          -  Other drugs with approval from sponsor.\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  CD4 count < 200 cells/mm3.\n\n          -  Cytomegalovirus ( CMV ) viruria and virosemenia.\n\n          -  No evidence of intraocular CMV.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Acute or chronic cardiovascular, pulmonary, renal, hepatic, pancreatic, hematologic,\n             endocrine, neurological, or other unstable illness.\n\n          -  Inability to take oral medication.\n\n          -  Allergy to nucleoside analogs.\n\n          -  Diarrheal illness.\n\n          -  Poor venous access.\n\n          -  Positive test for drugs of abuse.\n\n          -  Any other condition that would render patient unsuitable for study.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of pancreatitis.\n\n          -  Recent diarrheal illness.\n\n          -  History of weight loss.\n\n          -  Acute serious illness within 4 weeks prior to study entry.\n\n        Prior Medication:\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Erythropoietin.\n\n          -  Any agent with anti-CMV activity.\n\n          -  Other investigational agents.\n\n        Prior Treatment:\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Surgery.\n\n          -  Blood transfusion. Drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "id_info": {
            "nct_id": "NCT00002352", 
            "org_study_id": "248A", 
            "secondary_id": "AI459-007"
        }, 
        "intervention": {
            "intervention_name": "Lobucavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Lobucavir"
            ]
        }, 
        "keyword": [
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "October 1, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Mount Zion Med Ctr / UCSF"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94121"
                    }, 
                    "name": "San Francisco Veterans Adm Med Cntr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "Univ of Minnesota"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002352"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {
        "Mount Zion Med Ctr / UCSF": "37.775 -122.419", 
        "San Francisco Veterans Adm Med Cntr": "37.775 -122.419", 
        "Univ of Minnesota": "44.98 -93.264"
    }
}